Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8058607 | 0.73 | DYRK1A (0.49) | DYRK1ACYP3A4ALDH1A1CYP1A2KDM4E | |
| SCHEMBL3817086 | 0.72 | MTOR (0.33) | DYRK1AALDH1A1CYP1A2KDM4EHSD17B10 | |
| SCHEMBL28547938 | 0.70 | DYRK1A (0.40) | DYRK1ACYP3A4ALDH1A1CYP1A2KDM4E | |
| SCHEMBL28547076 | 0.68 | DYRK1A (0.33) | DYRK1ACYP3A4 | |
| SCHEMBL249194 | 0.65 | DYRK1A (0.38) | DYRK1ACYP3A4ALDH1A1CYP1A2KDM4E | |
| SCHEMBL28540640 | 0.64 | DYRK1A (0.37) | DYRK1ACYP3A4CDK4CCND1 | |
| SCHEMBL28537969 | 0.64 | DYRK1A (0.37) | DYRK1ACYP3A4ALDH1A1CYP1A2LMNA | |
| SCHEMBL356854 | 0.64 | DYRK1A (0.35) | DYRK1ACYP3A4ALDH1A1CYP1A2LMNA | |
| SCHEMBL6648490 | 0.64 | DYRK1A (0.52) | DYRK1ACYP3A4ALDH1A1CYP1A2KDM4E | |
| SCHEMBL4500096 | 0.64 | CYP3A4 (0.69) | DYRK1ACYP3A4ALDH1A1CYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115350279-A | anti-HER 2 combinations for the treatment of tumors | 博笛生物科技有限公司 | 2022-11-18 | — | — | CN | disclosed |
| CN-115337402-A | Combination therapeutic compositions and combination therapeutic methods for treating cancer | 博笛生物科技有限公司 | 2022-11-15 | — | — | CN | disclosed |
| CN-115252792-A | anti-EGFR combinations for the treatment of tumors | 博笛生物科技有限公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-114716555-A | Compounds and compositions for targeting EGFR expressing tumors | 博笛生物科技有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114671954-A | Compounds and compositions targeting HER2 positive tumors | 博笛生物科技有限公司 | 2022-06-28 | — | — | CN | disclosed |
| EP-3937939-A1 | IMMUNE MODULATORY COMPOSITIONS AND METHODS FOR TREATING CANCERS | Birdie Biopharmaceuticals Inc. (KY) | 2022-01-19 | — | — | EP | disclosed |
| CN-113633783-A | Compounds and compositions for immunotherapy | 博笛生物科技有限公司 | 2021-11-12 | — | — | CN | disclosed |
| CN-105899539-B | Compounds and compositions for immunotherapy | 博笛生物科技有限公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-112587672-A | anti-PD-L1 conjugates for the treatment of tumors | 博笛生物科技有限公司 | 2021-04-02 | — | — | CN | disclosed |
| CN-112546231-A | Combination therapeutic compositions and combination therapeutic methods for treating cancer | 博笛生物科技有限公司 | 2021-03-26 | — | — | CN | disclosed |
| WO-2010066684-A2 | Pyridyloxyindoles Inhibitors of VEGF-R2 and Use Thereof for Treatment of Disease | NOVARTIS AG (CH) | 2010-06-17 | — | — | WO | disclosed |
| WO-2009089804-A1 | NOVEL CYTOSTATIC 7-DEAZAPURINE NUCLEOSIDES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR, V.V.I. (CZ) | 2009-07-23 | — | — | WO | disclosed |
| US-20080312206-A1 | Chemical Compounds-149 | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| EP-1984330-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2008-10-29 | — | — | EP | disclosed |
| EP-1979332-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2008-10-15 | — | — | EP | disclosed |
| EP-1966174-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007091046-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007083089-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007071955-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
| EP-1155698-A1 | ORGANOBORON COMPOUNDS EXHIBITING ANTICOCCIDIAL ACTIVITIES | Nitto Kasei Co., Ltd. (JP) | 2001-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312206-A1 | Chemical Compounds-149 | CSF3R, CSF1R, FLT3 | DYRK1A 967/4885CYP3A4 4528/4885ALDH1A1 1081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.